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OBJECTIVES We sought to improve regional myocardial delivery and subsequent collateral perfusion
induced by basic fibroblast growth factor-2 (FGF-2) using selective pressure-regulated
retroinfusion of coronary veins for delivery. This hypothesis was tested in a newly developed
pig model with percutaneous induction of chronic ischemia.
BACKGROUND Selective pressure-regulated retroinfusion of coronary veins is a catheter-based procedure that
has been shown to provide effective regional delivery of drugs and gene vectors into ischemic
myocardium.
METHODS A high-grade stenosis with subsequent progression to total occlusion within 28 days was
induced by implanting a reduction stent graft into the left anterior descending artery (LAD).
After seven days, a 30-min retroinfusion (anterior cardiac vein) was performed with (n  7)
or without (n 7) 150 g FGF-2 and compared with a 30-min antegrade infusion of 150 g
FGF-2 into the LAD (n  7). Sonomicrometry to assess regional myocardial function at rest
and during pacing, and microspheres to assess regional myocardial blood flow, were
performed 28 days after implantation of the reduction stent.
RESULTS Retroinfusion of FGF-2 compared favorably with controls and with antegrade infusion of
FGF-2 with regard to regional myocardial function at rest (18.5  4.1% vs. 5.7  2.9% vs.
7.9  1.8%, respectively, p  0.05) and during pacing. Regional myocardial blood flow was
also higher in the LAD territory after retroinfusion of FGF-2 (1.07  0.14 vs. 0.66  0.07
vs. 0.72  0.17 mlmin1g1, p  0.05).
CONCLUSIONS Selective pressure-regulated retroinfusion increased tissue binding of FGF-2 and enhanced
functionally relevant collateral perfusion compared with antegrade intracoronary delivery in
pigs with chronic myocardial ischemia. (J Am Coll Cardiol 2003;42:1120–8) © 2003 by
the American College of Cardiology Foundation
Angiogenic growth factors such as basic fibroblast growth
factor (FGF-2) and vascular endothelial growth factor
(VEGF) have been shown to induce collateral growth in
myocardial ischemia (1). Growth factors have been applied
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by injection into the myocardium (2) or by infusion into the
coronary artery (3–7). With regard to FGF-2, repeated
intracoronary bolus administration on two days was neces-
sary to improve myocardial perfusion by 31% in dogs (3). In
a pig model of chronic myocardial ischemia, a 6-g/kg
FGF-2 but not a 2-g/kg FGF-2 single intracoronary
treatment improved collateralization and regional myocar-
dial function (4), suggesting a dose-dependent effect of
FGF-2. Although antegrade administration of angiogenic
proteins has been promising in the ameroid constrictor pig
model (4), recent placebo-controlled clinical studies using
intracoronary delivery of recombinant VEGF-A165 or
FGF-2 showed only weak evidence for efficiency (8–10).
The short interval of time after intracoronary injection,
leading to limited tissue binding of the growth factor, may
result in inadequate local delivery of the angiogenic growth
factors to the ischemic myocardium (10).
In this study, we sought to increase the interval of time
and thereby enhance tissue binding of recombinant angio-
genic proteins by delivery into the coronary vein using
catheter-based selective pressure-regulated retroinfusion
(11). It has been shown previously that selective pressure-
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regulated retroinfusion results in highly efficient and re-
gional targeting of drugs and reporter genes to ischemic
myocardium (12–14). Hence, the aim of the present study
was to investigate whether selective pressure-regulated ret-
roinfusion of recombinant FGF-2 into coronary veins in-
duces functionally relevant collateral perfusion, and to com-
pare this delivery method with antegrade delivery into the
coronary artery.
METHODS
The investigation followed the “Guide for the Care and Use
of Laboratory Animals” (NIH Publication No.85-23, re-
vised 1985) and was approved by the Bavarian Animal
Care- and Use-Committee (AZ 2511-106/99).
The study was carried out in 52 German farm pigs (28 
3 kg). Seven pigs were used to establish the reduction-stent
model; six pigs were used for binding experiments at day
seven; 21 pigs were used for assessment of therapeutic
angiogenesis at day 28 after three different treatment pro-
tocols at day seven (groups A, B, C). Of the remaining 18
pigs, 11 pigs died before reaching day seven, and five pigs
were excluded because of complete occlusion of the reduc-
tion stent at day seven. Another two pigs (1 of group A,
1 of group C) died before reaching day 28 and were also
excluded from analysis.
All pigs were premedicated with clopidogrel (300 mg)
and aspirin (300 mg). Anesthesia was induced by intramus-
cular ketamine (500 mg) and azaperone (10 mg/kg) and
maintained by midazolam IV, piritramide IV, and inhaled
Enflurane 0.5% to 2.0%. Pigs were mechanically ventilated.
A catheter introducer-sheath was placed into the carotid
artery, and heparin 20,000 IU IV was injected.
Induction of chronic myocardial ischemia by implanta-
tion of a reduction stent into the left anterior descending
artery (LAD). A coronary polytetrafluoroethylene-covered
stent-graft (Jomed, Germany) of 13 mm length was
placed on a 1.5 mm diameter needle, and a ligature was
placed around the middle of the stent (Fig. 1A). Thereafter,
the stent was crimped on a percutaneous transluminal
Abbreviations and Acronyms
CX  circumflex artery
FDG  fluorodeoxyglucose
FGF-2  fibroblast growth factor-2
LAD  left anterior descending artery
LV  left ventricle/ventricular
MI  myocardial infarction
PET  positron emission tomography
VEGF  vascular endothelial growth factor
Figure 1. Induction of chronic myocardial ischemia using a reduction stent. (A) A stent graft is ligated in the center. (B) The stent is crimped on balloon
and inflated at 14 atm; it remains unexpanded at the site of the ligature, resulting in an hourglass-shaped stenosis. (C) Postmortem angiogram at day 28.
The arrow indicates the location of the reduction stent, which is totally occluded. Collaterals are visible connecting the proximal left anterior descending
artery (LAD) and diagonal branches to the distal LAD.
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angioplasty-balloon (20 mm length/3.0 mm diameter)
(Fig. 1B) and implanted (14 atm) into the proximal LAD in
all 52 pigs. The stent remained unexpanded at the site of the
ligature, resulting in an hourglass-shaped stenosis (Fig. 1B).
The degree of stenosis calculated from the cross-sectional
area at the site of the ligature (1.8 mm2) and at the expanded
edges of the stent (7.1 mm2) was 75%. An antiplatelet and
anticoagulation regimen consisting of clopidogrel 75 mg
PO, ASA 100 mg PO, and reviparine 0.25 ml SC was
administered daily for 28 days.
After seven days, the degree of LAD stenosis at the site
of the stent was reexamined (fluoroscopy). If the stent was
occluded, pigs were excluded from further analysis (n  5).
In all other pigs, hemodynamics and left ventricular (LV)
function (LV end-systolic and end-diastolic pressures,
dp/dtmax, dp/dtmin) were measured using a microtip catheter
(Millar). Cardiac output was determined by thermodilution.
Application of FGF-2. Seven days after implantation of
the reduction stent and after fluoroscopic control of the
patency of the stent, pigs were treated by retroinfusion of
saline (controls, group A, n  7) or 150 g FGF-2
(retroinfusion, group B, n  7). In group C (n  7), pigs
were treated with antegrade intracoronary infusion of
150 g FGF-2 into the LAD.
In groups A and B, a 6F 4-lumen retroinfusion catheter
was selectively placed into the anterior cardiac vein (12–14).
Pressure-regulated retroinfusion of arterial blood without
suction was carried out for 30 min with a preset retroinfu-
sion pressure of about 20 mm Hg higher than the systolic
coronary venous occlusion pressure, resulting in a mean
retroinfusion pressure of 58  9 mm Hg. Heparinized
saline solution containing 150 g FGF-2 (Peprotech, Ger-
many) was continuously added to the retroinfused arterial
blood throughout the 30-min treatment period in group B,
whereas heparinized saline solution alone was added in the
controls (group A). In group C, heparinized saline solution
containing 150 g FGF-2 was continuously infused during
30 min into the LAD proximal to the reduction stent.
In six additional experiments, the binding of 125iodine-
labeled FGF-2 was studied to compare antegrade and
retrograde application. Fibroblast growth factor-2 was ra-
diolabeled using the chloramine T-catalyzed iodination
method similar to that previously described in detail (15).
Specific radioactivity of the iodinated FGF-2 was 11 Ci/
Figure 2. Regional perfusion map of the left ventricular after slicing from the basis to the apex. (A) Seven days after implantation (n  7). Diamond line
 rest; square line  adenosine. Continued on next page.
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g. [125I]Fibroblast growth factor-2 retained full biological
activity in a proliferation assay (data not shown). In six pigs
with similar high-grade stenosis seven days after implanta-
tion of the reduction stent, 30 g [125I]FGF-2 and 120 g
unlabeled FGF-2 were applied during 30 min, either by
antegrade infusion (LAD) or by pressure-regulated retro-
infusion (anterior cardiac vein). Forty-five minutes after
application, the pigs were euthanized, and transmural sam-
ples from the targeted LAD territory and the nontargeted
circumflex artery (CX) territory and different organs were
harvested and measured using a -counter (LKB, Sweden).
Regional myocardial blood flow. Regional myocardial
blood flow was measured using fluorescent labeled micro-
spheres (16). Briefly, 1  107 microspheres were injected
into the left atrium (Molecular-Probes) for each measure-
ment. Reference blood samples were withdrawn from the
abdominal aorta at a rate of 4.1 ml/min.
In seven pigs used to establish the reduction-stent model,
regional myocardial blood flow was studied at rest and
during adenosine-induced flow reserve (80 gkg1min1
intracoronary) using different colors of microspheres seven
and 28 days after implantation of the reduction-stent graft.
Regional myocardial blood flow at rest and during pacing
(110 beats/min) was determined at day 28 after implanta-
tion of the reduction stent in groups A, B, and C. In all pigs,
two transmural myocardial samples were obtained from the
proximal and distal ischemic LAD territory and one sample
from the CX territory after euthanasia. Samples were divided
into endocardial, midmyocardial, and epicardial probes. Fluo-
rescence was measured using a sample processing unit (16).
Regional myocardial function. Subendocardial segment
shortening was determined by sonomicrometry (HSE, Ger-
many) (17). After sternotomy, three pairs of 5-MHz ultra-
sonic crystals were implanted in two defined areas of the
ischemic LAD territory (1 cm and 3 cm distal to the
reduction stent) and in the CX territory.
Capillary density. The central slice of each transmural
myocardial probe was used for assessment of capillary density.
Alkaline phosphatase staining was performed (18) and sepa-
rately analyzed by two investigators blinded to the groups.
Collateral score. An in vivo angiogram was performed
prior to thoracotomy (Exposcop 8000, Ziem, Germany).
For assessment of collateral arteries, a postmortem angio-
gram was obtained (Coroskop HIP, Siemens, Germany) by
Figure 2 Continued. (B) Twenty-eight days after implantation (n  7). Diamond line  rest; square line  adenosine. Adenosine  regional myocardial
perfusion determined after intracoronary adenosine; LAD  left anterior descending artery; probe  number of transmural probes; rest  regional
myocardial perfusion at rest.
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flushing the coronaries of the excised heart with saline and
0.2 mg glyceryl-trinitrate, followed by injection of 10 ml
contrast agent into the left coronary artery (100 mm Hg). In
the postmortem angiogram, collateral arteries connecting
the CX, the proximal LAD, or the first diagonal branch
with the distal LAD were counted by two separate investi-
gators blinded for the groups (19).
Assessment of infarct size and viability. In seven pigs
used to establish the reduction-stent model, infarct size was
determined at 28 days by tetrazolium-chloride staining
followed by slicing of the LV (14) using computer based
planimetry (SigmaScan-Pro). In groups A, B, and C myo-
cardial infarction (MI) was determined at day 28 by mor-
phometric assessment and by histology after standardized
sampling of nine representative transmural probes (0.5 cm
in diameter) of the entire LAD territory (1 cm, 2 cm, and 3
cm distal to the reduction stent as well as 0.5 cm, 1.5 cm,
and 2.5 cm perpendicular to the LAD). Each sample was
cut on a microtome (15 m sections; hemalaun-eosine
staining) and assessed for the presence of MI.
Fluorodeoxyglucose (FDG)-positron emission tomogra-
phy (PET). Dynamic PET was performed in three pigs of
the control group using a whole-body scanner (CTI/ECAT
951R/31; Siemens, Germany). Twenty mCi of 13N-labeled
ammonia (13NH3) were administered intravenously (30 s).
Dynamic PET acquisition was performed using varying
frame durations (12 10 s, 6 30 s, and 3 300 s). Thirty
minutes later 10 mCi of 18FDG were injected and dynamic
image acquisition was repeated. A threshold of50% of the
maximum pixel count density was used for defining areas
with significant reduction in 13NH3 uptake (perfusion
defect). Further processing and analysis comprised myocar-
dial rate of glucose uptake in 18FDG study.
Statistical analysis. All data were analyzed using SPSS.
Data are presented as mean  standard error of the mean
(SEM). The investigators performing the experiments at
day 28 were blinded for the assigned treatment groups at
day seven. Differences between groups A, B, and C were
assessed with ANOVA. In case of statistically significant
differences with ANOVA, two group comparisons were
Figure 3. Polar map display of relative myocardial uptake of 18fluorodeoxyglucose (18FDG) and 13N-labeled ammonia (13NH3). The most basal LV wall
segments are depicted in the most peripheral rings, whereas the most apical occupies the center of the map. S  septum; I  inferior; L  lateral; A 
anterior. Segments with brighter colors (white, red) present higher uptake values. There is a large 13NH3 uptake defect in left anterior descending artery
territory corresponding to 20% of the left ventricular. In the same area, increased uptake of 18FDG is observed.
Table 1. Hemodynamics
Group A Group B Group C
Day 7 Day 28 Day 7 Day 28 Day 7 Day 28
Heart rate [beats/min] 73.3  0.9 79.0  2.8 74.0  10.0 74.0  3.5 74.8  1.8 76.3  3.1
LVPsys [mm Hg] 74.0  2.5 80.8  9.2 77.0  15.4 78.0  2.8 77.2  4.5 79.1  3.3
LVEDP [mm Hg] 10.7  3.8 16.5  2.1* 9.5  5.2 10.8  1.6 10.2  3.2 14.3  1.5
Cardiac output [l/min] 2.6  0.5 3.4  0.4 2.4  0.4 3.3  0.2 2.5  0.3 3.3  0.4
dP/dtmax [mm Hg/s2] 886  123 861  81 957  245 1115  371 902  81 921  110
dP/dtmin [mm Hg/s2] 1036  99 870  306 1029  111 963  125 1010  98 880  156
*p  0.05 group A vs group C at day 28. Group A  controls; group B  pigs treated by retroinfusion of fibroblast growth factor-2; group C  antegrade infusion of fibroblast
growth factor-2. Measurements were carried out 7 and 28 days after implantation of the reduction-stent.
dP/dtmax peak velocity of left ventricular pressure rise; dP/dtmin peak velocity of left ventricular pressure fall; LVEDP left ventricular end diastolic pressure; LVPsys
systolic left ventricular pressure.
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performed using Mann-Whitney test. A p value 0.05 was
considered statistically significant.
RESULTS
Implantation of the reduction stent resulted in a calculated
degree of stenosis of about 75%. In the seven pigs used to
establish the reduction-stent model, the angiographically de-
termined degree of stenosis was 72 3% and progressed to 91
 3% after seven days. After 28 days, the LAD was totally
occluded in all pigs (Fig. 1C). Seven days after implantation of
the reduction stent, regional myocardial blood flow at rest and
adenosine-induced flow reserve were significantly decreased in
the dependent LAD territory (Fig. 2A).
Twenty-eight days after implantation of the reduction
stent, the decrease in regional myocardial blood flow at rest
was even more pronounced (Fig. 2B), with a mean of
0.65  0.1 mlmin1g1 vs. 1.41  0.15 mlmin1g1 in
the CX territory. 13N-labeled ammonia- and 18FDG-PET
was performed in three pigs of the control group and
confirmed the presence of under-perfused but viable myo-
cardium in the LAD territory at 28 days (Fig. 3). Infarct size
determined by tetrazolium staining at 28 days (n  7) was
2.0  0.4% of the LV mass. Before treatment at day seven,
groups A, B, and C were similar with regard to the degree
of LAD stenosis (91  3% vs. 92  2% vs. 92  2%,
respectively) and systemic hemodynamics (Table 1).
Tissue binding of [125I]FGF-2. To compare tissue bind-
ing of [125I]FGF-2 after antegrade and retrograde delivery,
radioactivity was determined in myocardial samples har-
vested 45 min after application at day seven in six pigs. After
antegrade application, calculated FGF-2 retained in the
targeted LAD territory was about 4.5  1% (n  3). After
selective pressure-regulated retroinfusion, binding of
FGF-2 in the targeted LAD territory was increased twofold
to about 11  2% (n  3) (Fig. 4); thus, binding of
[125I]FGF-2 was increased 15- to 30-fold in the LAD
territory compared with in the CX territory. After retro-
grade administration, FGF-2 binding was significantly lower
in the lung (8,954  1,860 vs. 128,140  2,509 cpm/g, p 
0.05) but was not statistically different in the liver (84,148 
3,813 vs. 105,684  27,521 cpm/g) and in the spleen
(54,276  6,059 vs. 82,716  27,497 cpm/g).
Collateral score and capillary density. At day 28, the
number of visible collateral arteries at postmortem angiog-
raphy was higher in the retroinfusion group B (5.0  1.3;
p  0.05) compared with the control group A (2.95  0.4)
and with the antegrade group C (3.3  0.3). Similar results
were obtained with regard to capillary density (capillaries/
muscle fiber) being higher in group B (1.45  0.2; p 
0.05) than in group A (1.0  0.17) and group C (1.05 
0.15).
Figure 4. Tissue binding of 125iodine-labeled fibroblast growth factor-2 45
min after retroinfusion into the anterior cardiac vein (hashed bars, n  3)
or antegrade application into the left anterior descending artery (LAD)
(black bars, n  3). CX  circumflex artery.
Figure 5. Regional transmural myocardial blood flow at day 28 in the left anterior descending artery (LAD) territory. Left panel  at rest; right panel
 during pacing. Group A  controls; group B  retroinfusion of fibroblast growth factor-2; group C  antegrade delivery. *p  0.05.
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Regional myocardial blood flow. At day 28, regional
myocardial blood flow at rest in the LAD territory was
significantly higher in pigs treated with retroinfusion of
FGF-2 (group B) than in group A and in group C (Fig. 5):
1.07  0.14 mlmin1g1 vs. 0.66  0.07 mlmin1g1,
vs. 0.72  0.17 mlmin1g1. Of note, regional myo-
cardial blood flow in the ischemic LAD territory was
significantly lower than in the CX territory in all groups
(Table 2). There was a gradient from proximal to distal
probes and from the epicardial to the endocardial layers
within the LAD territory in all groups (Table 2). In pigs
treated by retroinfusion of FGF-2 (group B), this difference
was significant between the proximal and distal endocardial
probes (1.23 0.15 vs. 0.69 0.15 mlmin1g1). Under the
condition of increased oxygen demand during pacing (110
beats/min), regional myocardial blood flow in the LAD terri-
tory slightly increased in pigs of group B (retroinfusion of
FGF-2) but was unchanged in group A and group C (Fig. 5).
Regional myocardial function. The impact of FGF-2
treatment at day seven on regional myocardial function at
day 28 was studied at rest and during pacing. Substantial
preservation of regional myocardial function at day 28 was
observed within the LAD territory after retroinfusion of
FGF-2 at day seven in group B (Fig. 6). The efficacy,
however, decreased with the distance to the reduction stent.
In the proximal ischemic LAD territory (1 cm distal to the
reduction stent), subendocardial segment shortening was
well preserved in the retroinfusion group B (18.5 4.1% [%
end-diastolic length]) in contrast to controls (5.7  2.9%)
(Fig. 6, top panel). Similar results were obtained with regard
to pacing induced functional reserve. In the distal LAD
territory, regional myocardial function at rest was compro-
mised in all groups (Fig. 6, bottom panel). During pacing,
dyskinesia developed in groups A and C, in contrast to
group B (Fig. 6, bottom panel).
Global LV function. Global LV function was similar at
day seven in all groups (Table 1). Twenty-one days after
Table 2. Regional Myocardial Blood Flow
Group A Group B Group C
LAD prox
Epimyocardial 0.82  0.11 1.35  0.14* 1.06  0.20
Midmyocardial 0.67  0.08 1.28  0.13* 0.72  0.11
Endomyocardial 0.61  0.09 1.23  0.15* 0.65  0.23
LAD dist
Epimyocardial 0.70  0.04 0.82  0.13* 0.60  0.18
Midmyocardial 0.59  0.08 0.96  0.13* 0.68  0.14
Endomyocardial 0.55  0.04 0.69  0.15* 0.59  0.14
CX
Epimyocardial 1.46  0.08 1.49  0.11 1.47  0.13
Midmyocardial 1.32  0.11 1.36  0.10 1.41  0.12
Endomyocardial 1.21  0.06 1.21  0.13 1.27  0.15
Regional myocardial blood flow [ml/min/g]: group A (controls), group B
(retroinfusion of fibroblast growth factor-2) group C (antegrade infusion of
fibroblast growth factor-2); mean  SEM, n  7/group, *p  0.05 vs. control
(group A).
CX  circumflex artery; dist  distal; LAD  left anterior descending artery;
prox  proximal.
Figure 6. Regional myocardial function at day 28. White bars (group A)  controls; black bars (group B)  retroinfusion of fibroblast growth factor-2;
hashed bars (group C)  antegrade delivery. Top panel  proximal ischemic left anterior descending artery (LAD) territory; bottom panel  distal
ischemic LAD territory.
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treatment, however, LVEDP increased in the control group
A (16.5  2.1 mm Hg) and was significantly higher than in
the retroinfusion group B (10.8  1.6 mm Hg). Antegrade
infusion of FGF-2 (group C) was also associated with
higher LV end-diastolic pressure (14.3  1.5 mm Hg),
though less pronounced than in controls.
Infarct size. At day 28 after implantation of the reduction
stent, the extent of MI was not different in groups A, B, and
C determined by morphometric and histological assess-
ment. In nine representative probes of the LAD territory
assessed from each pig, transmural necrosis was found in
0.9  0.2 probes of group A, 1.0  0.2 probes of group B,
and 0.8  0.2 probes of group C. Focal necrosis was seen in
1.9  0.3 probes of group A, 1.9  0.4 probes of group B,
and 1.9  0.3 probes of group C.
DISCUSSION
Chronic myocardial ischemia induced by implantation of
a reduction stent. A novel catheter-based approach was
used in this study instead of surgical placement of an
ameroid constrictor (5,19) for induction of chronic myocar-
dial ischemia. Using a percutaneously implanted reduction
stent, a highly reproducible degree of LAD stenosis was
achieved acutely and the degree of stenosis increased from
about 72% to about 91% at seven days. Thus, regional
myocardial blood flow in the LAD territory was moderately
reduced at rest and flow reserve was significantly reduced
(Fig. 2A). Adenosine stress was used to assess flow reserve
and to compare it with the data known from the well-
established ameroid constrictor model (5,19,20). Similar to
the ameroid constrictor model, the time point of complete
occlusion of the coronary artery was not exactly defined after
implantation of the reduction stent. As the patency of the
stents at seven days was a prerequisite for the inclusion in
the treatment groups, total occlusion of the reduction stent
occurred between day seven and day 28 (Fig. 1C).
The extent of MI at day 28 in controls was similar to the
ameroid constrictor model applied in the CX in the pig (20).
In contrast to the ameroid constrictor model (21,22),
myocardial blood flow at rest was significantly reduced in
controls at day 28 (Fig. 2B). Accordingly, regional myocar-
dial function at rest was also impaired in the LAD territory,
in line with the definition of hibernating myocardium and
in agreement with the findings in a pig model of chronically
hibernating myocardium (23,24). The presence of hibernat-
ing myocardium at day 28 was also confirmed in an
exemplary fashion by the increased FDG uptake in the
under-perfused LAD territory (Fig. 3).
Angiogenic effects induced by selective pressure-
regulated retroinfusion of FGF-2. Selective pressure-
regulated retroinfusion into the coronary veins was used for
the first time to deliver recombinant angiogenic growth
factors into ischemic myocardium, in line with the concept
of prolonging contact time of drugs and gene vectors
(12–14). After retroinfusion of FGF-2 (day seven), the
number of collateral arteries visible at postmortem angiog-
raphy (day 28) was significantly increased compared with in
controls and with antegrade delivery. Although collateral
blood flow in pigs is very low in acute ischemia (25), the
development of collateral arteries has been described in case
of severe chronic ischemia (19,26). Hence, the development
of angiographically visible collateral arteries was enhanced
after retroinfusion of FGF-2.
Histology also showed increased capillary density in the
LAD territory 21 days after retroinfusion of FGF-2. Fur-
thermore, short-term treatment (30 min) by retroinfusion of
FGF-2 clearly enhanced tissue binding compared with
antegrade delivery (Fig. 4). About 5% of the applied
radioactivity was detected in the LAD territory after ante-
grade delivery of [125I]FGF-2, similar to results obtained in
a dog model (26). Retroinfusion resulted in an about
twofold increase in tissue binding of FGF-2 compared with
antegrade delivery, indicating successful targeting of FGF-2
to the ischemic myocardium. Because tissue binding of
FGF-2 was determined only once in our study (45 min after
application), we cannot exclude different redistribution ki-
netics with both modes of delivery.
Selective retroinfusion led to a 15- to 30-fold increase in
tissue binding of [125I]FGF-2 in the targeted ischemic
LAD territory compared with in the non-ischemic CX
territory. Nevertheless, systemic redistribution was present
with both delivery methods, especially to the lungs, the liver,
and the spleen. However, there were no abnormal macro-
scopic or histologic findings, such as hemangioma forma-
tion, in adjacent or remote organs.
Effects on regional myocardial blood flow and function.
The impact of arteriogenesis and angiogenesis on regional
myocardial blood flow and function was determined 21 days
after treatment. Of note, regional myocardial blood flow
was reduced under resting conditions in all three groups,
indicating the presence of ischemia in the LAD territory
(Fig. 5). The level of regional myocardial ischemia in the
LAD territory, however, was different in the three groups.
This difference was not explained by an imbalance in the
extent of MI between the three groups, which was ruled out
by morphometric and histological determination.
As expected from the increase in collaterals and the
density of capillaries, regional myocardial blood flow at rest
was higher in pigs treated by retroinfusion of FGF-2.
Improved regional myocardial blood flow in the LAD
territory of pigs treated by retroinfusion of FGF-2 was
accompanied by a significant preservation of regional myo-
cardial function, as segment shortening in the proximal
LAD territory was substantially higher at rest and during
increased oxygen demand. Increased oxygen demand by
atrial pacing was used instead of adenosine-induced flow
reserve to detect functional relevant recovery of hibernat-
ing myocardium. Thus, for the distal LAD territory,
differences in segment shortening between the groups
were detected during pacing, showing that regional
dyskinesia was prevented only after retroinfusion of
FGF-2 (Fig. 6). In contrast to the proximal LAD
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territory, the preservation of regional myocardial blood
flow in the distal LAD territory was not sufficient to
prevent myocardial dysfunction at rest, which is reason-
able for a decrease in subendocardial blood flow to 0.69 
0.15 mlmin1g1 in pigs (27).
Although there was a trend toward improved regional
myocardial blood flow and function in pigs treated by
antegrade infusion, this effect did not reach statistical
significance, which is in agreement with observations in
dogs after single antegrade injection of FGF-2 (3). A
limitation of the present study, however, is that treatment
groups were not randomly assigned.
Conclusions. We characterized a new pig model with
percutaneous induction of chronic myocardial ischemia and
with preliminary data indicating the development of hiber-
nating myocardium in the LAD territory. As catheter-based
access to the cardiac veins is not hampered, this model is
suitable for studying the effects of angiogenic proteins, such
as FGF-2 by retrograde delivery into the cardiac veins.
Selective pressure-regulated retroinfusion of FGF-2 signif-
icantly improved regional perfusion and function, suggest-
ing that retrograde FGF-2 delivery increased tissue binding
and targeted FGF-2 to vessel segments most receptive and
responsive to them (28,29). The preservation of regional
myocardial blood flow and function, however, was still
incomplete after the short-term (30 min) retrograde treat-
ment. Whether higher concentrations of FGF-2 or longer
retroinfusion periods might enhance the efficacy has not
been addressed in this study. Furthermore, the combined
application of FGF-2 with other angiogenic proteins might
be a promising approach based on reports of their synergis-
tic effects (18,30).
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